EGR2
E3 SUMO-protein ligase EGR2
Also known as: EGR2_HUMAN, KROX20
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- P11161
- Gene
- EGR2
- Ensembl
- ENSG00000122877
- Chromosome
- 10
- Canonical length
- 476 aa
- Protein class
- Disease related genes, Human disease related genes, Predicted intracellular proteins, Transcription factors
- Subcellular location
- Nucleoplasm
OverviewNCBI Gene
The protein encoded by this gene is a transcription factor with three tandem C2H2-type zinc fingers. Defects in this gene are associated with Charcot-Marie-Tooth disease type 1D (CMT1D), Charcot-Marie-Tooth disease type 4E (CMT4E), and with Dejerine-Sottas syndrome (DSS). Multiple transcript variants encoding two different isoforms have been found for this gene. [provided by RefSeq, Oct 2008]
Canonical amino-acid sequenceUniProt
476 residues, UniProt reviewed canonical sequence.
>P11161|EGR2
1 MMTAKAVDKI PVTLSGFVHQ LSDNIYPVED LAATSVTIFP NAELGGPFDQ MNGVAGDGMI
61 NIDMTGEKRS LDLPYPSSFA PVSAPRNQTF TYMGKFSIDP QYPGASCYPE GIINIVSAGI
121 LQGVTSPAST TASSSVTSAS PNPLATGPLG VCTMSQTQPD LDHLYSPPPP PPPYSGCAGD
181 LYQDPSAFLS AATTSTSSSL AYPPPPSYPS PKPATDPGLF PMIPDYPGFF PSQCQRDLHG
241 TAGPDRKPFP CPLDTLRVPP PLTPLSTIRN FTLGGPSAGV TGPGASGGSE GPRLPGSSSA
301 AAAAAAAAAY NPHHLPLRPI LRPRKYPNRP SKTPVHERPY PCPAEGCDRR FSRSDELTRH
361 IRIHTGHKPF QCRICMRNFS RSDHLTTHIR THTGEKPFAC DYCGRKFARS DERKRHTKIH
421 LRQKERKSSA PSASVPAPST ASCSGGVQPG GTLCSSNSSS LGGGPLAPCS SRTRTPLocalizationUniProt · AlphaFold · HPA
Whether an antibody against EGR2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.68
- Highest tissue expression
- 115 nTPM
Expression across tissuesHPA
Tissue
- thyroid gland: 115 nTPM
- epididymis: 56 nTPM
- gallbladder: 27 nTPM
- thymus: 23 nTPM
- cervix: 17 nTPM
- prostate: 16 nTPM
Single-cell type
- epididymal principal cells: 454 nCPM
- breast secretory cells: 116 nCPM
- epididymal basal cells: 79 nCPM
- breast myoepithelial cells: 44 nCPM
- macrophages: 42 nCPM
- respiratory basal cells: 40 nCPM
Immune cell
- intermediate monocyte: 2.3 nTPM
- non-classical monocyte: 2.2 nTPM
- classical monocyte: 0.4 nTPM
- memory B-cell: 0.4 nTPM
- myeloid DC: 0.4 nTPM
- naive B-cell: 0.4 nTPM
Brain region
- cerebral cortex: 19 nTPM
- hippocampal formation: 11 nTPM
- basal ganglia: 3.3 nTPM
- choroid plexus: 3 nTPM
- white matter: 3 nTPM
- cerebellum: 2.9 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about EGR2.
Disease | AllUniProt
Conditions EGR2 is implicated in, by any mechanism.
- Neuropathy, congenital hypomyelinating, 1, autosomal recessive (CHN1) MIM:605253
- Charcot-Marie-Tooth disease, demyelinating, type 1D (CMT1D) MIM:607678
- Dejerine-Sottas syndrome (DSS) MIM:145900
Disease | GeneticClinVar
18 pathogenic / likely-pathogenic of 463 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- Charcot-Marie-Tooth disease, type I
- Charcot-Marie-Tooth disease type 1D
- Dejerine-Sottas disease
- Charcot-Marie-Tooth disease
- Dejerine-sottas neuropathy, autosomal dominant
Disease | ImmuneIEDB
Conditions an epitope on EGR2 was assayed in.
- narcolepsy B cell
- multiple sclerosis B cell
- peripheral nervous system disease B cell
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.6
- gnomAD pLI
- 0.5
- gnomAD missense Z
- 2.44
- DepMap mean gene effect
- -0.27
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- aorta development
- brain development
- brain segmentation
- facial nerve structural organization
- fat cell differentiation
- gene expression
- motor neuron axon guidance
- myelination
- peripheral nervous system development
- positive regulation of DNA-templated transcription
- positive regulation of myelination
- positive regulation of Schwann cell differentiation
- positive regulation of transcription by RNA polymerase II
- protein export from nucleus
- protein sumoylation
- regulation of ossification
- regulation of transcription by RNA polymerase II
- rhythmic behavior
- Schwann cell differentiation
- skeletal muscle cell differentiation
- rhombomere 3 formation
- rhombomere 3 structural organization
- rhombomere 5 formation
- rhombomere 5 structural organization
Molecular functions
- chromatin binding
- DNA-binding transcription activator activity, RNA polymerase II-specific
- DNA-binding transcription factor activity
- DNA-binding transcription factor activity, RNA polymerase II-specific
- RNA polymerase II cis-regulatory region sequence-specific DNA binding
- RNA polymerase II-specific DNA-binding transcription factor binding
- sequence-specific DNA binding
- sequence-specific double-stranded DNA binding
- SUMO ligase activity
- transcription cis-regulatory region binding
- ubiquitin protein ligase binding
- zinc ion binding
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of EGR2 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads EGR2 as an antibody target. Whether an autoantibody or antibody against EGR2 could matter depends on whether native EGR2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
EGR2 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label EGR2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...